ANDA 206396, held by Cipla. Palonosetron Hydrochloride.
As of Nov 16, 2026, ANDA 206396 (Palonosetron Hydrochloride), held by Cipla, was first approved by FDA on Sep 19, 2018, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 19, 2018 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Palonosetron HydrochlorideEQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) · injectable;intravenous | Palonosetron Hydrochloride | Discontinued |
| May 21, 2025 | Supplement 4Labeling · Standard review | Approved | None posted |
| Oct 30, 2019 | Supplement 1Labeling · Standard review | Approved | None posted |
| Sep 19, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters